Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type

[1]  J. Ajani,et al.  Targeted literature review of the global burden of gastric cancer , 2018, Ecancermedicalscience.

[2]  S. Green,et al.  Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial , 2018, Supportive Care in Cancer.

[3]  M. Aapro,et al.  Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations , 2017, Drug design, development and therapy.

[4]  A. Molassiotis,et al.  The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Yan Jiang,et al.  A network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic/advanced breast cancer , 2016, Oncotarget.

[6]  E. Bruera,et al.  2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  F. Kikkawa,et al.  A prospective observational study on chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer by the CINV Study Group of Japan. , 2016, Gynecologic oncology.

[8]  C. Gridelli,et al.  Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. , 2015, The Lancet. Oncology.

[9]  B. Hutton,et al.  Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea? , 2015, The oncologist.

[10]  M. Aapro,et al.  Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. , 2015 .

[11]  M. Aapro,et al.  Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types. , 2013, Cancer treatment reviews.

[12]  M. Kris,et al.  American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Hesketh.  Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. , 1999, The oncologist.

[14]  M Nurminen,et al.  Comparative analysis of two rates. , 1985, Statistics in medicine.

[15]  M. Kris,et al.  Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Green,et al.  Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  H. Satoh,et al.  Chemotherapy-induced complications in patients with lung cancer: An evaluation by pharmacists. , 2013, Molecular and clinical oncology.

[18]  M. Kris,et al.  Antiemetics: American Society of Clinical Oncology clinical practice guideline update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.